CASPER MARC N sold $161K of TMO

CASPER MARC N (Chairman & CEO) sold 275 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $586.10 ($577.37–$593.32, $0.16M total) across 15 trades on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 10, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest information is the specific open-market sale details: 275 shares sold across 15 trades at a weighted average price of $586.1038, totaling $161,178.54, with holdings after the sale of 123,925 shares.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a fundamental repricing.

03

What to watch

The filing does not indicate intent beyond the plan; without additional context (e.g., multiple consecutive sales, buybacks, or earnings proximity), the signal is weak.

Relevance 3/10Novelty 5/10Timing: Filed after-hours on 2026-08-10, disclosing trades executed 2026-08-07.

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported by its Chairman & CEO.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher CEO/C chairman Casper Marc N sold $161,178 of TMO shares via an open-market sale under a 10b5-1 plan on 2026-08-07.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction, but it is explicitly tied to a pre-arranged 10b5-1 plan and the dollar amount is small relative to a mega-cap, reducing signal strength.

Market effects

No clear sector read-through; this is company-specific insider activity without operational or regulatory linkage.

Minimal, as the disclosure is unlikely to move broader US healthcare/life-science tools sentiment.

Limited, since the event is a routine insider sale at a US-listed large-cap.

Counterpoint

Even 10b5-1 sales can coincide with periods of elevated valuation or personal liquidity needs, so traders may still fade near-term strength if flows look persistent.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider transaction disclosure.

  • CASPER MARC N

    Chairman & CEO who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TMOMed

Thermo Fisher Scientific Replenishes Buyback Capacity to $5 Billion

Thermo Fisher Scientific (TMO) authorized up to $5B in new stock repurchases, replacing a prior authorization with $1B remaining. The company spent $4B on buybacks in 2026's first nine months, with no purchases in Q3. Operating cash flow increased to $5.867B for the period, with $4.618B in free cash flow. The new authorization complements acquisitions, dividends, and debt obligations.